Relmada Therapeutics Inc
RLMD
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
98.6% downsideOvervalued by 98.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $528.74 Million |
|---|---|
| Enterprise Value | $518.96 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.43 |
| Outstanding Shares | 86,596,873 |
Return
| Return on Equity | -26.92% |
|---|---|
| Return on Assets | -25.02% |
| Return on Invested Capital | -27.23% |
Valuation & Multiples
| P/E Ratio | -10.6 |
|---|---|
| PEG | -124.76 |
| Price to Sales | - |
| Price to Book Ratio | 3.17 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.57 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1371▲ 7.63% |
|---|---|
| Total Calls | 341,300▲ 77.39% |
| Total Puts | 46,800▲ 300.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 211.91%▲ 58.51% |
|---|---|
| Total Invested | $581.48M▲ 136.59% |
| Investors Holding | 108▲ 24.00% |
ESG Score
No data
About Relmada Therapeutics Inc
14 employees
CEO: Sergio Traversa Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed to making a difference ...
Relevant Senate Committees
This non-partisan committee provides the official 'revenue estimates' (scoring) for all tax bills, directly influencing corporate tax structures and capital investment credits. Its technical expertise dictates the fiscal landscape for companies like Relmada Therapeutics.
This committee controls taxation, trade, and entitlement spending. Tax policy directly impacts corporate profitability for Relmada Therapeutics, and its influence on Medicare pricing and other entitlement spending is highly relevant for the market access and reimbursement of pharmaceutical products.
This committee allocates discretionary federal spending. Its subcommittees determine the precise funding levels for agencies like NIH (research) and healthcare programs (e.g., VA, Medicare/Medicaid through other committees' jurisdiction) that are crucial for the biotechnology sector and potential drug procurement.
This committee regulates the FDA and NIH. FDA oversight of drug approval is the primary regulatory gatekeeper for a late-stage biotechnology company like Relmada Therapeutics, directly impacting its ability to bring products to market.
This committee oversees the DOJ, antitrust laws, and intellectual property (IP). Intellectual property protection (patents) is absolutely critical for biotechnology companies like Relmada Therapeutics, making this committee highly relevant for their core business model.